Biosimilar User Fee Act

RIN

—

Last modified

Jan 2, 2026

Comment window

closed 207d ago

American Pharmacists Association (APhA) filings

Activity

American Pharmacists Association (APhA) filed 1 comment on this docket between Dec 6, 2021 and Dec 6, 2021. 13 other organizations filed here. The comment window closed 207d ago.

What American Pharmacists Association (APhA) filed (1)

Dec 6, 2021· Comment from American Pharmacists Association (APhA)· FDA-2015-N-3326-0041

Please see the attached comments of the American Pharmacists Association (APhA) on "Reauthorization of the Biosimilar User Fee Act (BsUFA III)." APhA supports BsUFA's goal of ensuring the efficiency and effectiveness of the biosimilar biological product review program, as well as enhancing biosimilar and interchangeable biological product development for optimal care and access for patients.

View on regulations.gov →

Abstract

No abstract recorded.

View on regulations.gov →

Co-filers (13)

See everyone who commented →

American Pharmacists Association (APhA)THIS ORG
1 filing · confidence 97%
Association for Accessible Medicinestrade assoc.
3 filings · confidence 97%
Arthritis Foundationtrade assoc.
2 filings · confidence 85%
American Federation of Statetrade assoc.
1 filing · confidence 85%
Biologics Coalitiontrade assoc.
1 filing · confidence 85%
CELLTRION Inc.unverified attribution
1 filing · confidence 70%
Generic Pharmaceutical Association (GPhA) and Biosimilar Counciltrade assoc.
1 filing · confidence 85%
Generic Pharmaceutical Association (GPhA) and Biosimilars Counciltrade assoc.
1 filing · confidence 85%
Healthcare Supply Chain Associationtrade assoc.
1 filing · confidence 85%
Hepatitis Foundation Internationaltrade assoc.
1 filing · confidence 85%
National Consumers Leaguetrade assoc.
1 filing · confidence 85%
Pfenex Incunverified attribution
1 filing · confidence 70%
Pfizer Inc.unverified attribution
1 filing · confidence 70%
The Alliance for Safe Biologic Medicinestrade assoc.
1 filing · confidence 85%